摘要
平眩胶囊作为拥有专利的特色彝族药物,具有滋补肝肾、平肝潜阳的功效,主要用于治疗肝肾不足、肝阳上扰所致眩晕、头痛、心悸耳鸣、失眠多梦、腰膝酸软,临床广泛运用于治疗后循环缺血性眩晕、前庭性偏头痛、良性阵发性位置性眩晕等疾病,但目前对该药的疗效证据、辨证要点、用药安全性的认识尚不充分.故本文在总结临床医师用药经验基础上,结合现有循证证据,邀请来自全国相关领域的临床中、西医专家,药学专家和方法学专家,遵循中华中医药学会标准化办公室《中成药临床专家共识研制技术规范》,通过建议评估制定评价证据分级系统(GRADE)进行循证评价形成了 5条推荐意见和16条共识建议,明确了平眩胶囊治疗眩晕的临床应用范围、疗效、剂量、疗程、联合用药、注意事项、禁忌人群等问题,并说明临床应用的安全性.本共识适用于全国三级医院、二级医院、基层医疗卫生机构的临床医师(中医、西医、中西医结合专业)、药师,为合理使用平眩胶囊治疗眩晕提供参考.希冀该共识的推广能促进临床科学合理用药,减少用药风险,进一步发挥该药在治疗眩晕疾病的优势.本共识已通过中华中医药学会的审核,并进行了发布,编号GS/CACM 330-2023.
Abstract
As a patented characteristic medicine of Yi ethnic minority,Pingxuan capsules have the effects of nourishing the liver and kidney,pacifying the liver,and subduing Yang.With the main indications of dizziness,headache,palpitations,tinnitus,insomnia,dreaminess,waist and knee soreness caused by liver-kidney deficiency and liver Yang upward disturbance,Pingxuan capsules are widely used in the treatment of posterior circulation ischemic vertigo,vestibular migraine,benign paroxysmal positional vertigo.However,the current knowledge is limited regarding the efficacy,syndrome differentiation,and safety of this medicine.On the basis of summarizing the experience of clinicians and the existing evidence,this study invites clinical experts of traditional Chinese and Western medicine,pharmaceutical experts,and methodological experts from relevant fields across China to conduct evidence-based evaluation of Pingxuan capsules.The evaluation follows the Specifications for the Development of Clinical Expert Consensus on Chinese Patent Medicines issued by the Standardization Office of the China Association of Chinese Medicine,and reaches 5 recommendations and 16 consensus suggestions.The consensus clarifies the clinical applications,efficacy,dose,course of treatment,combination of medicines,precautions,and contraindications of Pingxuan capsules in the treatment of vertigo and explains the safety of clinical application.This consensus is applicable to clinicians(traditional Chinese medicine,Western medicine,and integrated traditional Chinese and Western medicine)and pharmacists in tertiary hospitals,secondary hospitals,and community-level medical and health institutions across China,providing a reference for the rational use of Pingxuan capsules in the treatment of vertigo.It is hoped that the promotion of this consensus can facilitate the rational use of drugs in clinical practice,reduce the risk of drug use,and give full play to the advantages of Pingxuan capsules in the treatment of vertigo diseases.This consensus has been reviewed and published by the China Association of Chinese Medicine,with the number GS/CACM330-2023.
国家科技期刊平台
NSTL
维普
万方数据